28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD. 3 key findings →
Design: clinical trial Participants: 1,684 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. 5 key findings →
Design: open-label trial Participants: 63 Evidence: high
Full summary, score breakdown and related studies → Original source
72 patients with PDD or DLB were randomly assigned and started treatment: 34 with memantine and 38 with placebo. 56 (78%) completed the study. 2 key findings →
Participants: 72 Evidence: high
Full summary, score breakdown and related studies → Original source
No significant differences were found in the primary efficacy analysis. 2 key findings →
Design: clinical trial Participants: 234 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus. 2 key findings →
Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The dual primary efficacy endpoint was not reached. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study failed to find a beneficial effect of exogenous melatonin, consistent with a number of other studies. 2 key findings →
Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The objective of our study was to assess the efficacy and safety of donepezil in young adults with Down syndrome (DS) but no evidence of Alzheimer disease (AD). 2 key findings →
Design: open-label trial Participants: 123 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This double-blind randomized controlled trial of vitamin therapy demonstrates a strong correlation between serum tHcy and plasma Abeta40 concentrations in subjects with ischemic stroke. 4 key findings →
Design: randomized controlled trial Participants: 150 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
14 studies were identified that matched inclusion criteria. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Overall, 318 patients with AD completed BPST with an improvement of 5.6 points on the total Cohen-Mansfield Agitation Inventory (CMAI; mean [SD], 63.3 [16.0] to 57.7 [18.4], t = 4.8, df = 317, p 95% of patients. 2 key findings →
Design: randomized controlled trial Participants: 318 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Enrollment began in March 2001 and ended in December 2004 when treatments were suspended because of concerns regarding cardiovascular safety of the treatments. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Addition of ATX to ongoing cholinesterase-inhibitor therapy was generally well tolerated but did not significantly improve cognitive function. 5 key findings →
Participants: 92 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Earlier NH admission of Australian compared to U.K. and U.S. subjects may be due to differences in health care, NH systems, availability, and affordability. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Donepezil and memantine have similar modest clinical and spectroscopic effect on mild to moderate AD. 3 key findings →
Design: randomized controlled trial Participants: 32 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Treatment success in Alzheimer disease (AD) trials is generally based on benefits over placebo-treated controls. 2 key findings →
Participants: 3,403 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Rivastigmine therapy for PDD is associated with significant tradeoffs in efficacy and adverse effects. 5 key findings →
Design: randomized controlled trial Participants: 541 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Efforts to use plasma levels of Abeta peptides as AD biomarkers or disease-staging scales have failed. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The MAPT Study is the first preventive trial involving multidomain interventions. 2 key findings →
Participants: 300 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Use of cholinesterase inhibitors is associated with increased rates of syncope, bradycardia, pacemaker insertion, and hip fracture in older adults with dementia. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
This paper is based on a presentation made during the Indiana Alzheimer Disease Center's Symposium on Mild Cognitive Impairment on April 19, 2008. 3 key findings →
Participants: 3,000 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Estrogen-containing hormone therapy initiated during late postmenopause does not improve episodic memory (an important early symptom of Alzheimer's disease), and it increases dementia risk. 1 key finding →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Menopause is associated with sharp declines in concentrations of circulating estrogens. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There are no empiric data to support guidelines for duration of therapy with antidementia drugs. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The groups of individuals who agreed to participate in the imaging substudies of AD trials were remarkably comparable to the comparison groups at baseline on a wide range of demographic and clinical measures; there seems to be a minimal effect of self-selection bias. 4 key findings →
Participants: 166 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →